X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1203) 1203
Publication (162) 162
Book Chapter (10) 10
Book Review (7) 7
Dissertation (3) 3
Conference Proceeding (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (720) 720
metronomic chemotherapy (709) 709
index medicus (678) 678
oncology (648) 648
chemotherapy (550) 550
cancer (503) 503
female (422) 422
angiogenesis (329) 329
male (326) 326
animals (317) 317
administration, metronomic (277) 277
cyclophosphamide (276) 276
middle aged (251) 251
aged (237) 237
therapy (213) 213
adult (200) 200
treatment outcome (196) 196
antineoplastic combined chemotherapy protocols - therapeutic use (192) 192
mice (191) 191
tumors (180) 180
cyclophosphamide - administration & dosage (175) 175
metastasis (165) 165
pharmacology & pharmacy (157) 157
bevacizumab (156) 156
care and treatment (154) 154
breast-cancer (152) 152
neoplasms - drug therapy (149) 149
breast cancer (148) 148
endothelial growth-factor (136) 136
antineoplastic combined chemotherapy protocols - administration & dosage (134) 134
research (131) 131
cell line, tumor (129) 129
antineoplastic agents - administration & dosage (122) 122
phase-ii (120) 120
metronomic (116) 116
cancer therapies (112) 112
phase-ii trial (112) 112
tumor angiogenesis (111) 111
analysis (110) 110
angiogenesis inhibitors - therapeutic use (109) 109
breast neoplasms - drug therapy (103) 103
survival (101) 101
drug therapy (100) 100
angiogenesis inhibitors - administration & dosage (99) 99
antineoplastic combined chemotherapy protocols - adverse effects (98) 98
disease-free survival (98) 98
health aspects (98) 98
medicine & public health (98) 98
aged, 80 and over (96) 96
dose-response relationship, drug (96) 96
drug administration schedule (95) 95
capecitabine (94) 94
antineoplastic agents - therapeutic use (91) 91
neovascularization, pathologic - drug therapy (91) 91
antitumor-activity (89) 89
administration, oral (87) 87
immunotherapy (87) 87
vascular endothelial growth factor (87) 87
trial (84) 84
clinical trials (83) 83
hematology, oncology and palliative medicine (83) 83
xenograft model antitumor assays (81) 81
metastatic breast-cancer (80) 80
antineoplastic agents (79) 79
combination (77) 77
paclitaxel (77) 77
antimitotic agents (76) 76
cancer research (76) 76
efficacy (76) 76
breast neoplasms - pathology (74) 74
toxicity (73) 73
antiangiogenic therapy (72) 72
drug dosages (72) 72
article (71) 71
hematology (71) 71
neoplasm metastasis (71) 71
apoptosis (70) 70
metronomic therapy (69) 69
solid tumors (69) 69
dosage and administration (65) 65
brain neoplasms - drug therapy (64) 64
methotrexate (64) 64
cells (63) 63
neoplasms - pathology (63) 63
prognosis (63) 63
vegf (63) 63
angiogenesis inhibitors - pharmacology (62) 62
antineoplastic agents, alkylating - administration & dosage (62) 62
mice, nude (62) 62
carcinoma (60) 60
cell proliferation - drug effects (60) 60
oral cyclophosphamide (60) 60
studies (59) 59
expression (58) 58
regulatory t-cells (58) 58
cyclophosphamide - therapeutic use (55) 55
drugs (54) 54
medicine, research & experimental (54) 54
neoplasm recurrence, local - drug therapy (54) 54
patients (54) 54
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1172) 1172
German (11) 11
Korean (11) 11
French (7) 7
Japanese (5) 5
Chinese (4) 4
Polish (3) 3
Russian (3) 3
Spanish (3) 3
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Pharmacology and Pharmacotherapeutics, ISSN 0976-500X, 2014, Volume 5, Issue 3, pp. 186 - 192
Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality... 
metronomic chemotherapy | Anti-angiogenesis | conventional chemotherapy | tumor dormancy | Chemotherapy | Care and treatment | Methods | Tumors | Cancer | Review
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 400, pp. 203 - 203
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 400, pp. 282 - 292
Abstract Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of cancer treatment for more than half a century. In some... 
Hematology, Oncology and Palliative Medicine | Metronomic chemotherapy | Immunotherapy | Cancer therapy | LOW-DOSE CYCLOPHOSPHAMIDE | IMPROVES SURVIVAL | TUMOR ANGIOGENESIS | ONCOLOGY | INHIBITS ANGIOGENESIS | COLORECTAL-CANCER | ACUTE LYMPHOBLASTIC-LEUKEMIA | PROSTATE-CANCER | REGULATORY T-CELLS | ORAL TOPOTECAN | ANTITUMOR IMMUNITY | Tumor Escape - drug effects | Immunotherapy - methods | Administration, Metronomic | Humans | Immunologic Factors - administration & dosage | Neovascularization, Pathologic | Neoplasms - blood supply | Treatment Outcome | Antineoplastic Agents - administration & dosage | Immunotherapy - adverse effects | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Neoplasms - therapy | Animals | Antineoplastic Agents - adverse effects | Neoplasms - immunology | Immunologic Factors - adverse effects | Neoplasms - pathology | Medical colleges | Chemotherapy | Analysis | Drug resistance | Drug therapy | Health aspects | Cells | Tumors | Cancer | Defensive behavior | Cytotoxicity | Metastasis | Cancer therapies | Blood | Adoptive transfer | Ovarian cancer | Anticancer properties | Proteins | Angiogenesis | Cell growth | Bone marrow | Inhibition | Vascular endothelial growth factor | Drug dosages | Deoxyribonucleic acid--DNA | Antigens | Autografts | Cytokines | Melanoma | Immunodeficiency | Cell division | Blood vessels | Lymphatic leukemia | Equilibrium | Sun | Disease control | Endothelium | Inhibitors | Blood circulation | Lymphomas | Mice | Angiogenesis inhibitors | Kidney transplantation | Ovarian carcinoma | Leukemia | Medical services | Kinases | Dormancy | Heterogeneity | Immunology | Lymphocytes | Modulation | Cell cycle | Immune system | Acute lymphatic leukemia | Immune response | Dendritic cells | Hematology | Tumor cells | Vessels | Feasibility studies | Light emitting diodes | Breast cancer | Pharmacology | Chemical compounds | Lymphoma | Cell death | Adenoviruses | Cells (biology) | Breast | Antitumor activity | Interferon | Differentiation | Apoptosis | Index Medicus
Journal Article
Oral Oncology, ISSN 1368-8375, 2014, Volume 51, Issue 3, pp. 279 - 286
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 400, pp. 232 - 242
Abstract The therapeutic concept of administering chemotherapeutic agents continuously at lower doses, relative to the maximum tolerated dose (MTD) without... 
Hematology, Oncology and Palliative Medicine | Nanoparticles | Tumor priming | Maximum tolerated dose | Liposomes | Dosing schedule | Metronomic chemotherapy | ADVANCED HEPATOCELLULAR-CARCINOMA | PEGYLATED LIPOSOMAL DOXORUBICIN | LOW-DOSE CYCLOPHOSPHAMIDE | STEM-LIKE CELLS | ONCOLOGY | ACCELERATED BLOOD CLEARANCE | METASTATIC BREAST-CANCER | COATED CATIONIC LIPOSOMES | RECURRENT OVARIAN-CANCER | COLORECTAL TUMOR-MODEL | ENDOTHELIAL GROWTH-FACTOR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Neoplasms - blood supply | Drug Carriers | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Maximum Tolerated Dose | Animals | Neoplasms - immunology | Nanomedicine - methods | Drug Compounding | Neoplasms - pathology | Angiogenesis Inhibitors - adverse effects | Angiogenesis Inhibitors - chemistry | Drugs | Antimitotic agents | Chemotherapy | Drug delivery systems | Pharmacy | Drugstores | Development and progression | Antineoplastic agents | Cancer | Vehicles | CD8 antigen | Cytotoxicity | Metastasis | Drug resistance | Cancer therapies | Blood | Anticancer properties | Metastases | Angiogenesis | Breast carcinoma | Bone marrow | CD25 antigen | Inhibition | Drug dosages | Antigens | Macromolecules | Blood vessels | Exposure | Ablation | Carriers | Inhibitors | Surveillance | Antigen-presenting cells | Stem cells | Angiogenesis inhibitors | Accessibility | Toxicity | Dormancy | Lymphocytes | Modulation | Immune system | Effectiveness | Tumor cells | Vessels | Pharmacology | Breast cancer | Inflammation | Permeability | CD4 antigen | Hypotheses | Cell death | Antigen (tumor-associated) | Breast | Antitumor activity | Microenvironments | Cations | Pharmacokinetics | Tumors | Apoptosis | Index Medicus
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2016, Volume 13, Issue 11, pp. 659 - 673
Metronomic chemotherapy describes the close, regular administration of chemotherapy drugs at less-toxic doses over prolonged periods of time. In 2015, the... 
IN-VITRO | ANTIANGIOGENIC ACTIVITY | ONCOLOGY | RANDOMIZED PHASE-II | BREAST-CANCER PATIENTS | ANTITUMOR INNATE IMMUNITY | ORAL TOPOTECAN | CYCLOPHOSPHAMIDE TREATMENT | ANTICANCER DRUGS | CLINICAL PHARMACOKINETICS | DOSE CHEMOTHERAPY | Angiogenesis Inhibitors - immunology | Pyrimidines - immunology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Breast Neoplasms - immunology | Alkylating Agents - immunology | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Colorectal Neoplasms - drug therapy | Tubulin Modulators - administration & dosage | Alkylating Agents - pharmacokinetics | Camptothecin - administration & dosage | Female | Camptothecin - immunology | Camptothecin - pharmacokinetics | Pyrimidines - administration & dosage | Tubulin Modulators - pharmacokinetics | Alkylating Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Breast Neoplasms - drug therapy | Forecasting | Randomized Controlled Trials as Topic | Immunity, Cellular - immunology | Colorectal Neoplasms - immunology | Tubulin Modulators - immunology | Pyrimidines - pharmacokinetics | Chemotherapy | Care and treatment | Patient outcomes | Forecasts and trends | Pharmacokinetics | Observations | Methods | Cancer | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2017, Volume 141, Issue 9, pp. 1912 - 1920
Journal Article